<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02023606</url>
  </required_header>
  <id_info>
    <org_study_id>810P111</org_study_id>
    <nct_id>NCT02023606</nct_id>
  </id_info>
  <brief_title>Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M</brief_title>
  <official_title>An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and Excretion (AME) of [14C] Labeled SPN-810M in Healthy Adult Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and
      Excretion of Radio Labeled SPN-810M in Healthy Adult Male Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary and fecal recoveries (mass balance) of total radioactivity.</measure>
    <time_frame>10 days post dose.</time_frame>
    <description>C(urine and feces), Ae(urine and feces), CumAe(urine and feces), % Dose(urine and feces), CUM% Dose(urine and feces).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole blood and plasma partitioning of total radioactivity.</measure>
    <time_frame>10 days post dose.</time_frame>
    <description>To determine whole blood and plasma partitioning of total radioactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of total radioactivity in plasma.</measure>
    <time_frame>10 days post dose.</time_frame>
    <description>PK of total radioactivity in plasma (Cmax, Tmax, AUC0-t, AUCinf, Kel, and t1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of SPN-810 in plasma.</measure>
    <time_frame>10 days post dose.</time_frame>
    <description>PK of SPN-810 in plasma (Cmax, Tmax, AUC0-t, AUCinf, Kel, and t1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of the major metabolites of SPN-810 in plasma.</measure>
    <time_frame>10 days post dose.</time_frame>
    <description>PK of the major metabolites of SPN-810 in plasma (Cmax, Tmax, AUC0-t, AUCinf, Kel, and t1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites of SPN-810 in plasma, urine and feces</measure>
    <time_frame>10 days post dose.</time_frame>
    <description>To characterize and identify the metabolites of SPN-810 in plasma, urine and feces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of SPN-810.</measure>
    <time_frame>10 days post dose.</time_frame>
    <description>To assess the safety and tolerability of SPN-810 by collecting Adverse Events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Impulsive Aggression Comorbid With ADHD</condition>
  <arm_group>
    <arm_group_label>SPN-810M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 20 mL solution containing 50 mg of SPN-810M and no less than 8.5 MBq (225 µCi) carbon-14 (14C)-SPN-810M, and no more than 11.3 MBq (305 µCi) [14C] SPN-810M.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPN-810M</intervention_name>
    <arm_group_label>SPN-810M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Entry:

          1. Healthy males.

          2. Aged 30 to 55 years.

          3. Considered medically healthy by the Investigator via assessment of physical
             examination, medical history, clinical laboratory tests, urinalysis, vital signs, and
             electrocardiogram.

          4. Able to voluntarily provide written informed consent to participate in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jo Collier, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2013</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impulsive Aggression</keyword>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Impulsive Behavior</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

